The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...

Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...

Moderna said the approval was supported by a study showing the vaccine is safe and works well for younger adults (ages 18 to 59) with medical conditions. Their immune response was just as strong ...

The vaccine was previously only licensed for adults aged 60 years and older. “RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step ...

The vaccine was previously only licensed for adults aged 60 years and older. “RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step ...